drugset / Trial / NCT01789242
A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis
NaSingle-groupOpen-labelTreatment
Summary
This is a dose finding study to evaluate the safety and determine the maximum tolerated dose of carfilzomib in patients with previously treated systemic light-chain amyloidosis.
Timeline
- Start
- 2013-02
- Primary completion
- 2016-12
- Completion
- 2017-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carfilzomib | Other / unclassified | — | Intravenous |
| Background | Dexamethasone | Small molecule | — | Intravenous |